Respiratory Syncytial Virus (RSV) is a common respiratory virus that typically causes mild, cold-like symptoms. While most people recover within a week or two, RSV can be serious, especially for infants and older adults, potentially leading to bronchiolitis or pneumonia. The development of RSV vaccines offers a way to protect vulnerable populations from severe disease, aiming to reduce hospitalizations and other severe outcomes.
Prescription Requirements for RSV Vaccines
Accessing the RSV vaccine for adults aged 60 and older often does not require a prescription. Many states permit pharmacists to administer vaccines, including the RSV vaccine, under a standing order or statewide protocol. This allows individuals to receive the vaccine directly at a retail pharmacy. Regulations vary by state, so checking with a local pharmacy is advisable.
When receiving the RSV vaccine at a doctor’s office or other clinical setting, a healthcare provider will order or prescribe the vaccine. This ensures the vaccine is integrated into the patient’s medical record and that any specific health considerations are reviewed by the physician. For pregnant individuals, the RSV vaccine, such as Abrysvo, is administered in a clinical setting, where a prescription or order from their obstetrician is part of the standard care pathway.
Eligibility and Access to the RSV Vaccine
The Centers for Disease Control and Prevention (CDC) recommends RSV vaccination for specific groups. Adults aged 60 years and older are advised to discuss RSV vaccination with their healthcare provider. This age group faces an increased risk of severe outcomes, including hospitalization and death.
Pregnant individuals are also recommended to receive an RSV vaccine during their third trimester, specifically between 32 and 36 weeks of gestation. This maternal vaccination transfers protective antibodies to the developing fetus, providing passive immunity to the newborn during their first few months of life. This protects infants, who are highly susceptible to severe RSV disease.
Individuals can access the RSV vaccine at various locations. Retail pharmacies are a common site for vaccination, offering walk-in or scheduled appointments. Physician’s offices and other healthcare clinics also provide the vaccine. Some public health clinics may also offer RSV vaccination services.
Key Information About the RSV Vaccine
Currently, there are two RSV vaccines approved for use in the United States for different populations: Arexvy and Abrysvo. Arexvy is approved for individuals 60 years of age and older, designed to protect this older adult population from severe RSV disease. This vaccine targets a specific protein on the surface of the RSV virus to elicit an immune response.
Abrysvo is approved for two populations: adults 60 years of age and older, and pregnant individuals to protect their infants. For older adults, it functions similarly to Arexvy by stimulating an immune response against the virus. When administered to pregnant individuals, Abrysvo helps their bodies produce antibodies that cross the placenta, offering newborns protection against RSV infection.
The purpose of these RSV vaccines is to prevent serious illness, hospitalizations, and fatalities caused by Respiratory Syncytial Virus. By stimulating the immune system to recognize and fight off the virus, the vaccines help reduce the burden of RSV disease, especially in populations at higher risk for severe complications. This preventative measure contributes to public health by mitigating the impact of seasonal RSV outbreaks.